PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/203468

Please be advised that this information was generated on 2020-03-11 and may be subject to change.
Exome sequencing in families with chronic central serous chorioretinopathy

Rosa L. Schellevis1* | Elon H. C. van Dijk2* | Myrte B. Breukink1 | Jan E. E. Keunen1 | Gijs W. E. Santen3 | Carel B. Hoyng1 | Eiko K. de Jong1 | Camiel J. F. Boon2,4 | Anneke I. den Hollander1,5

1Department of Ophthalmology, Donders Institute of Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands
2Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
3Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
4Department of Ophthalmology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5Department of Human Genetics, Donders Institute of Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

Correspondence
Anneke I. den Hollander, Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
Email: Anneke.denhollander@radboudumc.nl

Funding information
Nijmeegse Oogonderzoek Stichting; UitZicht; Landelijke Stichting voor Blinden en Slechtienden; Haagse Stichting Blindenhulp; Stichting Blindenhulp; Stichting Nederlands Oogheelkundig Onderzoek; Macula Vision Research Foundation; ZonMw VENI Grant; Stichting A.F. Deutman Oogheelkundige Researchfonds; MaculaFonds; Gisela Thier Fellowship; Gelderse Blindenstichting; Retina Netherlands; BlindenPenning; Radboud Institute of Molecular Life Sciences; Rotterdamse Stichting Blindenbelangen

Abstract
Background: Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by fluid accumulation between the neuroretina and retinal pigment epithelium with unknown etiology. Family studies have suggested a heritable component for CSC with an autosomal dominant inheritance pattern. Therefore, exome sequencing was performed on familial cCSC to identify the genetic components contributing to familial cCSC.

Methods: Exome sequencing was performed on 72 individuals of 18 families with CSC. In these families, we determined whether rare genetic variants (minor allele frequency < 1%) were segregated with CSC and also performed familial gene-burden analysis.

Results: In total, 11 variants segregated in two out of 18 families. One of these variants, c.4145C>T; p.T1382I (rs61758735) in the PTPRB gene, was also associated with CSC in a large case–control cohort sequenced previously (p = 0.009). Additionally, in 28 genes two or more different heterozygous variants segregated in two or more families, but no gene showed consistent associations in both the family gene-burden results and gene-burden analysis in the case–control cohort.

Conclusion: We identified potential candidate genes for familial CSC and managed to exclude Mendelian inheritance of variants in one or a limited number of genes. Instead, familial CSC may be a heterogeneous Mendelian disease caused by variants in many different genes, or alternatively CSC may represent a complex disease to which both environmental factors and genetics contribute.

Keywords
chronic central serous chorioretinopathy, exome sequencing, families, PTPRB, RareIBD

*These authors should be considered joint first author.
1 | INTRODUCTION

In central serous chorioretinopathy (CSC), choroidal congestion, thickening, and hyperpermeability have been suggested to cause leakage through the retinal pigment epithelium (RPE). Subsequently, a neuroretinal detachment occurs due to the accumulation of serous subretinal fluid (Daruich et al., 2015; Gemenetzi, De Salvo, & Lottery, 2010; Liew, Quin, Gillies, & Fraser-Bell, 2013; Warrow, Hoang, & Freund, 2013; Yannuzzi, 2010). The exact etiology of CSC is still unclear, but male gender and administration of exogenous corticoids have been described to be the most pronounced risk factors for CSC (Carvalho-Recchia et al., 2002; Haimovici, Koh, Gagnon, Lehrfeld, & Wellik, 2004; Jonas & Kampf, 2005). Other risk factors include endogenous hypercortisolism, stress, and pregnancy (Daruich et al., 2015; van Dijk et al., 2016; Liew et al., 2013). Moreover, genetic variants that confer risk or are protective for CSC have been identified by genetic association studies in case–control cohorts (de Jong et al., 2015; Miki et al., 2014; Moschos et al., 2016; Schellevis et al., 2018; Schubert et al., 2014; van Dijk, Schellevis, Bergen et al., 2017).

Although familial occurrence of CSC appears to be rare, several reports on familial CSC and the occurrence of CSC in multiple generations within a single family have been published, pointing to a potential role for genetic factors in familial CSC (Lin, Arrigg, & Kim, 2000; Oosterhuis, 1996; van Dijk, Schellevis, Breukink et al., 2017; Weenink, Borsje, & Oosterhuis, 2001). A Mendelian inheritance of CSC has been proposed previously based on observations that at least two family members proved to have finding characteristics for CSC in 52% of 27 families (Weenink et al., 2001). Moreover, the presence of affected individuals in multiple generations has been described, suggesting an autosomal dominant mode of inheritance of familial CSC (van Dijk, Schellevis, Breukink et al., 2017). Additionally, in 50% of eyes from screened family members of CSC patients, a thickened choroid (pachychoroid) of more than 395 μm was detected, which has been described to be the underlying choroidal abnormality in various diseases that are part of the pachychoroid spectrum (Lehmann, Bousquet, Beydoun, & Behar-Cohen, 2015). However, thus far no genetic studies on familial CSC have been conducted.

Whole-exome sequencing has proven to be a powerful tool to identify novel disease-associated genes and gene variants in many disorders (Gilissen et al., 2010; Gilissen, Hoischen, Brunner, & Veltman, 2012). Exons are presumed to harbor about 85% of disease-causing mutations, making them a primary target to search for disease-associated variants in CSC families (Choi et al., 2009). Therefore, we performed exome sequencing on 72 individuals of 18 families in which multiple members were found to have CSC, in order to determine whether Mendelian inheritance of rare genetic variants causes familial CSC.

2 | MATERIALS AND METHODS

2.1 | Ethical compliance

Written informed consent for the enrollment was obtained from all subjects. The study adhered to the tenets of the Declaration of Helsinki. Approval of the institutional review boards and the ethics committees was obtained for all centers involved.

2.2 | Subject selection

In this multicenter study, 72 subjects from 18 families, including patients with CSC and unaffected family members, visited either the Department of Ophthalmology of the Radboud University Medical Center ([Radboudumc] Nijmegen, the Netherlands) or the Leiden University Medical Center ([LUMC] Leiden, the Netherlands). Participants were recruited at the outpatient clinic of the participating hospitals, after the proband had reported a family history of CSC. The majority of the individuals was included in our previously published study on the phenotypic characteristics of familial CSC and was divided in the following groups: “Affected with CSC,” “Suggestive of CSC,” or “Unaffected,” using the criteria described before (van Dijk, Schellevis, Breukink et al., 2017).

Briefly, subjects were categorized as having CSC when serous fluid was detected on an optical coherence tomography scan and when one or more “hot spots” of leakage or diffuse leakage was present in combination with irregular RPE window defects on fluorescein angiography. Patients were excluded if signs of either polyoid choroidal vasculopathy or age-related macular degeneration (AMD), or other atypical findings were present. Suggestive CSC was characterized by RPE alterations typical for CSC, but without the presence of either subretinal fluid or ‘hot spots’ of leakage on fluorescein angiography (van Dijk, Schellevis, Breukink et al., 2017). Unaffected individuals showed no abnormalities on any of the modalities using multimodal imaging.

2.3 | Exome sequencing

Library preparation of the 52 family members of 12 families collected at the Radboudumc, Nijmegen was performed with the SureSelectXT target enrichment system for Illumina paired-end multiplex sequencing according to manufacturer's instructions (Version B4, August 2015, Agilent Technologies). Completed libraries were sent to the Department of Genetics of Maastricht University Medical Center+, Maastricht, the Netherlands, where sequencing was performed with eight samples per lane using an Illumina HiSeq2000 with 2*100 bp chemistry, together with a large cohort of 269 sporadic CSC patients (Schellevis et al., 2018 submitted).
The 20 samples of the six families collected at Leiden University Medical Center, Leiden, the Netherlands were sent to GenomeScan BV, Leiden, for sequencing. For these samples, the Agilent SureSelect V5 enrichment kit was used and sequencing was performed with 2*125 bp chemistry on the HiSeq2500.

### 2.4 Variant calling and recalibration

Data of all individuals were processed according to the Genome-Analysis-Toolkit (GATK) best practices (v3.8) together with the case–control cohort consisting of 269 sporadic cCSC patients and 1,586 population controls (Schellevis et al., 2018 submitted) to improve variant calling. Briefly, BAM to FastQC extraction was performed with Picard-tools (v1.90), duplicate reads were marked with Picard-tools, and reads were aligned to the reference genome (GRCh37.p5 with alternate haplotypes excluded) using BWA-MEM (version v.0.7.12), as described before (Schellevis et al., 2018 submitted). Base recalibration was performed and subsequent variant calling was performed with the HaplotypeCaller algorithm. All GVCFs were merged together, and joint genotyping was performed on the entire dataset.

Variant recalibration was performed on the entire dataset with GATK using the recommended settings (McKenna et al., 2010), as described before. Genetic variants located in low complexity regions of the genome were removed (Li, 2014). Multiallelic variants were extracted with VCFtools (v0.1.13) and split using the splitMultiallelic and LeftAlignandTrimVariants option in GATK (v3.8). Variants with a Hardy–Weinberg equilibrium \( p < 1 \times 10^{-8} \) were excluded. Variants from the adult-onset genes captured in the American College of Medical Genetics and Genomics recommendations for incidental findings (BRCA1 [OMIM:113705], BRCA2 [OMIM:600185], MLH1 [OMIM:120436], MSH2 [OMIM:609309], MSH6 [OMIM:600678], PMS2 [OMIM:600259], MUTYH [OMIM:604933]) were removed to reduce the risk of secondary findings (Green et al., 2013; Kalia et al., 2017). Finally, family members were extracted from the dataset and only variants with a minor allele count \( \geq 1 \) in the combined family file were retained. Data were annotated with Tabanno (https://github.com/zhanxw/anno) and Annovar (Yang & Wang, 2015).

### 2.5 Variant filtering

Variants were filtered based on a minor allele frequency (MAF) of \( \leq 1\% \) or \( \geq 99\% \) in the following populations: 1000Genomes_all, 1000Genomes_European, Exac_All, Exac_NFE, Exac_FIN, and esp6500siv2_all. Additionally, variants with MAF \( \geq 1\% \) in the 1586 controls of the sporadic CSC case–control cohort were removed. Variants that were annotated by Annovar to be present in the exonic or splice site regions were retained and synonymous variants were excluded. Remaining variants included: frameshift insertions and deletions (INDELs), nonframeshift INDELs, nonsynonymous variants, stop gain or loss variants, and variants with unknown effects. All variants present in one or more unaffected individuals in any of the families were removed assuming complete penetrance, with the exception of the unaffected individual of Family 14, because based on the pedigree structure (Figure S1) reduced penetrance appeared to be present in this family. Only variants with a CADD score above 20, corresponding to the 1% most deleterious variants of the human genome, or with an unknown CADD score in case of INDELs, were retained.

Next, for each family segregation analysis of variants was performed, where variants were retained if they were present in all affected individuals of the family and not present in unaffected individuals. No filtering was performed for individuals with suggestive CSC. Variants that segregated in two or more families or genes that contained multiple variants that segregated in two or more families were retained for further evaluation. Familial gene-burden associations were calculated with RareIBD for those genes that carried multiple segregating variants in two or more families (Sul et al., 2016). The region encompassing the c.4145C>T; p.T1382I variant in the PTPRB [OMIM:176882] gene was amplified in additional family members of Family 1 using AmpliTaq DNA polymerase with the following PCR program: 5 min at 95°C, 10 cycles of touchdown starting at 62°C for 45 s and lowering the annealing temperature 0.5°C each cycle, followed by 25 cycles of an annealing temperature of 57°C, all these cycles started with 30 s at 95°C and ended 45 s at 72°C. The PCR was completed at 5 min, 72°C, and the following primers were used forward primer: AGCCTTTGAGCAGCTTTTTC and reverse primer: TGATGCTAGTGCCCCATAAG. The PCR product was analyzed by Sanger sequencing at the core sequencing facility at the Department of Human Genetics of the Radboudumc.

### 3 RESULTS

In this exome sequencing study on familial CSC, we included 72 individuals of 18 different families. Out of these 72 individuals, 33 subjects were affected with CSC, 18 had characteristics suggestive of CSC, and 21 were unaffected (Table 1; Figure 1 and Figure S1 for pedigrees). After variant filtering based on MAF (\( \leq 1\% \)), CADD score (\( \geq 20\) ), absence in unaffected individuals, and protein-altering effect (frameshift INDELs, nonframeshift INDELs, nonsynonymous, stop gain/loss variants, and variants with unknown effects), the dataset contained 2,806 variants present in 2,368 genes.
Segregation analysis was performed for all 18 families, retaining only variants that were present in the affected individuals and absent in unaffected individuals. The average number of segregating variants in each family was 44 and ranged from three to 124 (Table 1). In four families, two segregating heterozygous rare variants in the same gene were observed. Family 12 carried two variants in KCNMA1 [OMIM:600150], Family 7 in RBPJL [OMIM:616104], Family 8 in SLC26A10 [OMIM:NA], and Family 1 in SP9 [OMIM:NA] (Table S1). The entire list of segregating variants for each family is available in Table S2.

Variants that segregated in two or more families were retained for further evaluation. In total, 11 rare variants were found to segregate in two families, of which one variant in the PTPRB gene was homozygous in one individual, while the remaining variants in the SETD2 [OMIM:612778],

### Table 1: Overview of families analyzed for segregating rare variants using exome sequencing

| Family | No. of affected individuals | No. of suggestive individuals | No. of unaffected individuals | No. of segregating variants |
|--------|----------------------------|-------------------------------|-------------------------------|-----------------------------|
| Family 1 | 2                          | 3                             | –                            | 75                          |
| Family 2 | 2                          | –                             | –                            | 69                          |
| Family 3 | 1                          | 3                             | 2                            | 36                          |
| Family 4 | 1                          | 1                             | 4                            | 14                          |
| Family 5 | 1                          | 2                             | 4                            | 3                           |
| Family 6 | 2                          | 2                             | 1                            | 37                          |
| Family 7 | 1                          | 2                             | 3                            | 17                          |
| Family 8 | 3                          | –                             | 1                            | 17                          |
| Family 9 | 2                          | –                             | 2                            | 12                          |
| Family 10 | 2                         | 1                             | –                            | 58                          |
| Family 11 | 2                         | 1                             | –                            | 79                          |
| Family 12 | 3                         | –                             | –                            | 29                          |
| Family 13 | 2                         | –                             | –                            | 71                          |
| Family 14* | 2                        | –                             | 1                            | 37                          |
| Family 15 | 2                          | –                             | –                            | 60                          |
| Family 16 | 2                          | 1                             | 1                            | 21                          |
| Family 17 | 1                          | 1                             | –                            | 124                         |
| Family 18 | 2                          | 1                             | 2                            | 29                          |

*Possibly reduced penetrance in this family.
PWP1 [OMIM:NA], ABCA9 [OMIM:612507], AT2B2 [OMIM:NA], ZFAND4 [OMIM:NA], MROHS [OMIM:NA], ZAN [OMIM:602372], SHISA6 [OMIM:617327], DCP1A [OMIM:607010], and PPM1E [OMIM:NA] genes were heterozygous (Table 2). The expression of these genes in the retina and RPE was evaluated using the Eye Integration Database. All genes were expressed in retina and RPE, except for ZAN (Figure S2) (Bryan et al., 2018). The single variant association results of these variants were extracted from the sporadic CSC case–control dataset (Schellevis et al., 2018 submitted). Notably, the variant in the PTPRB gene (c.4145C>T; p.T1382I, rs61758735) was significantly associated with CSC in the case–control cohort ($p = 0.009$, Odds Ratio = 2.83, 95% Confidence Interval = 1.34–5.97).

Extended segregation analysis of the PTPRB variant in additional available family members of Family 1 revealed that two individuals carried the variant homozygously (one individual is an affected subject and one is a subject with findings suggestive of CSC), six individuals carried the variant heterozygously (two affected individuals, two individuals with findings suggestive of CSC, and two unaffected individuals), and one individual did not carry the variant (this individual had characteristics suggestive of CSC) (Figure 1a). Since two unaffected individuals (of which one individual was 74 years old at examination) carried the variant heterozygously, complete segregation of this variant with the disease in this family was not observed. For Family 2, no additional individuals were available for extended segregation analysis (Figure 1b).

As a next step, genes that contained multiple variants segregating in two or more families were evaluated. In 28 genes, we observed two or more different heterozygous variants that segregated in two or more families, including in two genes known to cause a retinal phenotype (ABCA4 [OMIM:601691] and VCAN [OMIM:118661]; full list of variants in Table 3). The expression of these genes in the retina and RPE was evaluated using the Eye Integration Database. All genes, with the exception of AGXT [OMIM:604285], LOXHD1 [OMIM:613072], and RBPL, showed moderate to high expression in the RPE or retina (Figure S3) (Bryan et al., 2018). For all 28 genes, the results of the gene-based analysis (Burden, SKAT, and SKAT-O) were extracted from the case–control analysis (Schellevis et al., 2018 submitted). Also, a family gene-burden analysis was performed with RareIBD including all rare variants found in all families in the 28 genes. Several genes were nominally associated with CSC, but no significant associations were observed in either of the tests after correction for multiple testing of 28 genes (Table 4). Additionally, no genes showed consistent associations in both the case–control cohort and the family cohort.

| Family Chr Position Rs‐number Gene Accession number Codon change Protein change CADD score Single variant $p$-value in case–control cohort $p$ | Family Chr Position Rs‐number Gene Accession number Codon change Protein change CADD score Single variant $p$-value in case–control cohort $p$ |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Family 7 + 14 3 4,716,897 rs114719990 SETD2 NM_014159 c.3229A>G p.T1077A 0.856 23.6 | Family 7 + 14 3 4,716,897 rs114719990 SETD2 NM_014159 c.3229A>G p.T1077A 0.856 23.6 |
| Family 13 + 17 12 108,105,893 rs11547909 PWP1 NM_007062 c.1402G>A p.E468K 0.801 24 |
| Family 2 + 17 17 67,013,913 rs143651746 ABCA9 NM_080283 c.2785T>C p.F929L 0.167 22.4 |
| Family 1 + 17 3 10,413,597 rs144118750 ATP2B2 NM_001683 c.1420G>A p.V474I 0.092 21.8 |
| Family 9 + 10 10 46,122,195 rs144142701 ZFAND4 NM_174890 c.1076T>A p.L359H 0.592 26.1 |
| Family 2 + 15 8 142,487,895 rs147691391 MROHS NM_207414 c.3469C>T p.S1160T 0.375 NA |
| Family 6 + 17 7 100,365,542 rs183014219 ZAN NM_173099 c.1346A>T p.E449V 0.407 24.7 |
| Family 3 + 13 17 11,459,147 rs185956842 SHISA6 NM_001173461 c.890C>T p.P297L 0.241 33 |
| Family 7 + 14 3 53,326,592 rs35988197 DCP1A NM_018403 c.890C>G p.A297G 0.278 24 |
| Family 1 + 2 12 70,949,014 rs61758735 PTPRB NM_001206971 c.4145C>T p.T1382I $0.009$ 27.8 |

$\text{chr}$, chromosome; NA, not annotated.

$p$-values lower than 0.05 are indicated in bold.
| Family | Chr | Position     | Rs-number       | Gene       | Accession number | Codon change | Protein change | Single variant p-value in cases control cohort | CADD score |
|--------|-----|--------------|-----------------|------------|-----------------|--------------|---------------|-----------------------------------------------|------------|
| 18     | 1   | 94,502,780   |                 | ABCA4      | NM_000350       | c.3734G>A    | p.S1245N      | NA                                            | 21.2       |
| 14     | 1   | 94,508,969   | rs61751374      | ABCA4      | NM_000350       | c.3113C>T    | p.A1038V      | 0.800                                          | 20.5       |
| 7      | 3   | 183,905,991  | rs566108440     | ABCF3      | NM_001351298    | c.614G>A     | p.R205Q       | 0.797                                          | 26.1       |
| 2      | 3   | 183,908,940  | rs77975407      | ABCF3      | NM_001351298    | c.1448C>T    | p.P483L       | NA                                             | 35         |
| 17     | 2   | 241,815,411  | rs140992177     | AGXT       | NM_0000030      | c.836T>C     | p.I279T       | 0.201                                          | 23.3       |
| 1      | 2   | 241,810,796  | rs121908524     | AGXT       | NM_0000030      | c.454T>C     | p.F152I       | 0.588                                          | 28.3       |
| 7      | 16  | 1,394,822    | 148966323       | BAIAP3     | NM_001199096    | c.1673C>T    | p.T558I       | 0.496                                          | 25.2       |
| 2      | 16  | 1,394,491    | rs144280977     | BAIAP3     | NM_001199096    | c.1516G>A    | p.D506N       | 0.052                                          | 22         |
| 2      | 8   | 139,833,569  | rs145361557     | COL2A1     | NM_152888       | c.1055G>A    | p.R352Q       | 0.823                                          | 23.1       |
| 12     | 8   | 139,838,971  | rs72731614      | COL2A1     | NM_152888       | c.899G>A     | p.R300Q       | NA                                             | 23.8       |
| 18     | 1   | 34,015,872   | rs149704396     | CSDM2      | NM_052896       | c.8390G>A    | p.R2797Q      | 0.079                                          | 22.8       |
| 14     | 1   | 34,066,488   | rs755952714     | CSMD2      | NM_001281956    | c.683G>A     | p.G2278E      | NA                                             | 24.9       |
| 1      | 17  | 1,944,871    | rs200625064     | DPH1       | NM_001346576    | c.778C>T     | p.Q260X       | NA                                             | 35         |
| 2      | 17  | 1,943,099    | rs80150196      | DPH1       | NM_001346576    | c.326C>G     | p.P109R       | 0.429                                          | 28.4       |
| 4      | 16  | 15,733,081   | rs150196755     | MARF1/     | NM_001184998    | c.10G>A      | p.G4R         | 0.718                                          | 28.6       |
|        |     |              |                 | KIAA0430   |                 |              |               |                                                |            |
| 6      | 16  | 15,729,650   | rs192438053     | MARF1      | NM_001184998    | c.694G>A     | p.G232R       | 0.495                                          | 25.8       |
| 1      | 6   | 138,655,606  | rs777828045     | ARFGEF3    | NM_020340       | c.5624_5626del| p.1875_1876del| 0.795                                          | NA         |
| 2      | 6   | 138,615,130  | rs755891726     | ARFGEF3    | NM_020340       | c.3369G>A    | p.R1123S      | 0.799                                          | 25.3       |
| 18     | 1   | 109,740,175  | rs940837035     | KIAAI324   | NM_001284353    | c.1188_1189del| p.I396fs      | 0.582                                          | NA         |
| 4      | 1   | 109,734,349  | rs41279690      | KIAAI324   | NM_001284353    | c.533G>A     | p.G178D       | 0.374                                          | 23.3       |
| 15     | 8   | 28,989,925   | rs145324154     | KIF13B     | NM_015254       | c.2842G>A    | p.A948T       | 0.573                                          | 32         |
| 11     | 8   | 29,102,864   | rsK15254        | KIF13B     | NM_015254       | c.148C>G     | p.R50G        | NA                                              | 27.8       |
| 13     | 7   | 91,871,373   | rs34358665      | KRIT1      | NM_001350672    | c.77G>A      | p.R26Q        | 0.542                                          | 23.6       |
| 12     | 7   | 91,851,344   |                 | KRIT1      | NM_001013406    | c.1291A>G    | p.K431E       | NA                                              | 24.2       |
| 17     | 18  | 44,089,726   | rs571539485     | LOXHDI     | NM_001145473    | c.169C>T     | p.P57S        | NA                                              | 25.6       |
| 7      | 18  | 44,140,215   | rs759237437     | LOXHDI     | NM_144612       | c.2891_2892insCTCATCAGAGGAGTCCCT     | S964delinsSSSEESS | 0.386 | NA |
| 1      | 14  | 74,971,538   | rs76036288      | LTBP2      | NM_000428       | c.4396G>A     | p.G1466R      | NA                                              | 32         |
| 15     | 14  | 74,967,643   |                 | LTBP2      | NM_000428       | c.5410T>G     | p.C1804G      | NA                                              | 27.2       |
| Family | Chr | Position | Rs-number | Gene | Accession number | Codon change | Protein change | Single variant p-value in cases control cohorta | CADD score |
|--------|-----|----------|-----------|------|------------------|--------------|---------------|-----------------------------------------------|------------|
| Family 6 | 17 | 10,426,647 | rs769778269 | MYH2 | NM_001100112 | c.5555G>A | p.R1852Q | NA | 33 |
| Family 11 | 17 | 10,424,643 | rs34161789 | MYH2 | NM_001100112 | c.5780G>A | p.R1927Q | 0.854 | 35 |
| Family 17 | 12 | 10,513,125 | rs367618675 | MYOF | NM_133337 | c.2024C>T | p.A675V | NA | 22 |
| Family 11 | 10 | 9,507,636 | rs146626145 | MYOF | NM_133337 | c.555C>T | p.A1851V | 0.248 | 23.8 |
| Family 3 | 6 | 32,180,684 | rs150079294 | NOTCH4 | NM_004557 | c.243T>G | p.C815G | 0.555 | 24.5 |
| Family 12 | 6 | 32,163,648 | rs764118051 | NOTCH4 | NM_004557 | c.557C>A | p.R1860S | NA | 34 |
| Family 9 | 17 | 10,424,643 | rs150079294 | NOTCH4 | NM_004557 | c.5780G>A | p.R1927Q | 0.854 | 35 |
| Family 11 | 10 | 9,507,636 | rs146626145 | MYOF | NM_133337 | c.555C>T | p.A1851V | 0.248 | 23.8 |
| Family 3 | 6 | 32,180,684 | rs150079294 | NOTCH4 | NM_004557 | c.243T>G | p.C815G | 0.555 | 24.5 |
| Family 12 | 6 | 32,163,648 | rs764118051 | NOTCH4 | NM_004557 | c.557C>A | p.R1860S | NA | 34 |

*p-values lower than 0.05 are indicated in bold; p-value from Schellevis et al., 2018 submitted; chr, chromosome; NA, not annotated.
For AMD, a well-studied multifactorial eye disease with phenotypic overlap with CSC, exome sequencing studies in families have been successful in identifying rare variants that fully or partially segregate with the disease (Geerlings et al., 2017; Hoffman et al., 2014; Pras et al., 2015; Saksens et al., 2016; Wagner et al., 2016; Yu et al., 2014). Most variants in these AMD families were identified in genes of the complement system, in which common and rare variants were previously identified to be associated with AMD in case–control cohorts (Fritsche et al., 2016). So far, the only genetic association that has been consistently been replicated in CSC was identified for common variants in the complement factor H (CFH [OMIM:134370]) gene (de Jong et al., 2015; Miki et al., 2014; Moschos et al., 2016; Schellevis et al., 2018). However, in this study, we did not observe any segregating rare variants in CFH in CSC families.

In this first unbiased exome sequencing study in a large cohort of families with CSC, we did not identify either a single variant or multiple variants in a single gene that segregated with the CSC phenotype. This excludes that familial CSC is a Mendelian disease caused by mutations in a single gene. Analysis of exome sequencing data identified numerous variants that segregate with the disease in each individual family. However, with this study setting, it is impossible to identify which of these variants might have an effect on the phenotype. Therefore, we focused on variants that segregated with CSC in at least two families, and on genes that carried multiple variants that segregated with CSC in at least two families.

In total, 11 segregating variants were observed in two families, of which the c.4145C>T; p.T1382I (rs61758735) variant in the PTPRB gene showed an association in the sporadic CSC case–control cohort (Schellevis et al., 2018 submitted). However, extended segregation analysis in additional family members excluded complete segregation of the PTPRB variant with the disease in one of two families. This is in line with results obtained in AMD families, in which rare variants did not always completely segregate with the disease (Duvvari et al., 2016; Geerlings et al., 2017; Hoffman et al., 2014; Saksens et al., 2016). Nevertheless, these variants are likely to contribute to the disease in these families, since several rare variants that are significantly associated with AMD in case–control studies often also show partial segregation in families (Geerlings et al., 2017; Saksens et al., 2016).

The PTPRB gene encodes the vascular endothelial protein tyrosine phosphatase (VEPTP) protein. Vascular endothelial protein tyrosine phosphatase is an important modulator of vascular endothelium morphogenesis and is involved in promoting angiogenesis and in regulating endothelial barrier functions by interacting with cadherin (Baumer et al., 2006; Nottebaum et al., 2008). Furthermore, intra-ocular injections of anti-VEPTP have been found to

### Table 4: Gene-based analysis results of the genes with multiple segregating variants in two or more families

| Gene     | Case–control analysisa | Family analysis |
|----------|------------------------|-----------------|
| ABCA4    | 0.074                  | 0.051           |
| ABCF3    | 0.386                  | 0.047           |
| AGX7     | 0.374                  | 0.301           |
| ARFGF3   | 0.126                  | 0.085           |
| BAIAP3   | 0.076                  | 0.143           |
| COL22A1  | 0.564                  | 0.020           |
| CSMD2    | 0.460                  | 0.328           |
| DPH1     | 0.039                  | 0.086           |
| KIAA1324 | 0.074                  | 0.097           |
| KIF13B   | 0.053                  | 0.288           |
| KRIT1    | 0.345                  | 0.021           |
| LOXHDI   | 0.567                  | 0.049           |
| LTPB2    | 0.378                  | 0.177           |
| MARF1    | 0.710                  | 0.094           |
| MYH2     | 0.858                  | 0.037           |
| MYOF     | 0.016                  | 0.144           |
| NOTCH4   | 0.544                  | 0.018           |
| PREX1    | 0.044                  | 0.061           |
| RBPIJ    | 0.131                  | 0.014           |
| RECQL4   | 0.234                  | 0.144           |
| RFT1     | 0.073                  | 0.019           |
| SETX     | 0.587                  | 0.169           |
| TCF25    | 0.782                  | 0.191           |
| TTN      | 0.577                  | 0.072           |
| USP20    | 0.426                  | 0.215           |
| VCAN     | 0.414                  | 0.144           |
| YLPM1    | 0.524                  | 0.047           |
| ZPLD1    | 0.237                  | 0.110           |

*p-values lower than 0.05 are indicated in bold; Burden, SKAT, and SKAT-O results were obtained from a recent case–control study performed with 263 sporadic CSC patients and 1,352 population controls (Schellevis et al., 2018 submitted).

### DISCUSSION

In this exome sequencing study on familial CSC, we included 72 individuals of 18 different families and focused on rare genetic variants that segregated with the disease in these families. We observed 11 variants that segregated in two families, of which one was also associated with CSC in a recent case–control study (Schellevis et al., 2018 submitted). In addition, in 28 genes two different variants were found to segregate in two families, and 25 of these genes showed expression in the retina or RPE according to the Eye Integration Database.
suppress neovascularization in mice (Shen et al., 2014). As it has been hypothesized that choroidal hyperpermeability and dysfunction is the most important underlying problem in CSC (Daruich et al., 2015), the \textit{PTPRB} gene is an interesting candidate gene for CSC and should be investigated in future studies. Variants in the \textit{PTPRB} gene could potentially predispose individuals to an impaired vascular network resulting in and leakage and occurrence of CSC. The remaining 11 variants were very rare or even absent in the case–control cohort, and we can neither rule out nor confirm their possible role in the CSC disease mechanism at this time.

In 28 genes, multiple different segregating variants were observed in at least two families. For these genes, gene-based associations in the case–control cohort (using SKAT, SKAT-O, and Burden test) and gene-based associations in the CSC families (using RareIBD) were evaluated. Five genes were nominally associated in the gene-burden analyses of the case–control cohort and nine genes were nominally associated in the family dataset. However, none of the genes showed consistent associations in both the gene-burden analysis in the case–control cohort and in the family gene-burden analysis. Of the five genes nominally associated in the case–control cohort, the \textit{DPH1} [OMIM:603527], \textit{KIAA1324} [OMIM:611298], and \textit{PREXI} [OMIM:606905] genes showed a trend toward association in the family dataset and might be interesting genes for replication in a larger CSC cohorts.

In summary, we aimed to identify rare variants associated with familial CSC. In each family, many variants segregated with the disease, but only few were found to segregate in at least two families. One of these variants was also associated with CSC in a recent case–control cohort (Schellevis et al., 2018 submitted), and this gene, \textit{PTPRB}, has a function that could be of importance in the etiology of CSC. Therefore, \textit{PTPRB} might be an interesting candidate gene for future studies on CSC. Future analyses should include additional families with more individuals to increase the chance of finding segregating variants in multiple families, and to increase the power of the RareIBD analysis. However, this may be challenging due to the relatively rare occurrence of familial CSC. Additionally, future studies may focus on the potential role of genetic variants in noncoding genetic regions, such as introns and promoter regions or large structural alterations that cannot be detected with exome sequencing, such as copy number variations.

In general, in familial CSC, a Mendelian inheritance pattern of variants in one or a limited number of genes can be excluded based on this study. Instead, familial CSC may be a heterogeneous Mendelian disease caused by variants in many different genes, or alternatively CSC may represent a complex disease to which both genetic and environmental factors contribute.

**ACKNOWLEDGMENTS**

This research was supported by the following foundations: MaculaFonds, Retina Netherlands, BlindenPenning, and Landelijke Stichting voor Blinden en Slechtzienden, that contributed through UitZicht, as well as Rotterdamse Stichting Blindenbelangen, Haagse Stichting Blindenhulp, ZonMw VENI Grant, and Gisela Thier Fellowship of Leiden University (CJFB), and Macula Vision Research Foundation, Stichting Nederlands Oogheelkundig Onderzoek, Stichting Blindenhulp, Stichting A.F. Deutman Oogheelkunde Researchfonds, Radboud Institute of Molecular Life Sciences, Gelderse Blindenstichting, and Nijmeegse Oogonderzoek Stichting (AldH&EKdJ). The funding organizations had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. They provided unrestricted grants.

**CONFLICT OF INTEREST**

None declared.

**ORCID**

Rosa L. Schellevis https://orcid.org/0000-0002-6939-8358

Elon H. C. van Dijk https://orcid.org/0000-0002-6351-7942

Gijs W. E. Santen https://orcid.org/0000-0003-1959-3267

Eiko K. de Jong https://orcid.org/0000-0001-6520-0407

Anneke I. den Hollander https://orcid.org/0000-0003-0634-5408

**REFERENCES**

Baumer, S., Keller, L., Holtmann, A., Funke, R., August, B., Gamp, A., ... Vestweber, D. (2006). Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. \textit{Blood}, 107(12), 4754–4762. https://doi.org/10.1182/blood-2006-01-0141

Bryan, J. M., Fufa, T. D., Bharti, K., Brooks, B. P., Hufnagel, R. B., & McGaughey, D. M. (2018). Identifying core biological processes distinguishing human eye tissues with precise systems-level gene expression analyses and weighted correlation networks. \textit{Human Molecular Genetics}, 27(19), 3325–3339. https://doi.org/10.1093/hmg/ddy239

Carvalho-Recchia, C. A., Yannuzzi, L. A., Negrao, S., Spaide, R. F., Freund, K. B., Rodriguez-Coleman, H., ... Iida, T. (2002). Corticosteroids and central serous chorioretinopathy. \textit{Ophthalmology}, 109(10), 1834–1837. https://doi.org/10.1016/S0161-6420(02)01117-X
Choi, M., Scholl, U. I., Ji, W., Liu, T., Tikhonova, I. R., Zumbo, P., … Lifton, R. P. (2009). Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proceedings of the National Academy of Sciences, 106*(45), 19096–19101. https://doi.org/10.1073/pnas.0910672106

Daruich, A., Matet, A., Dirani, A., Bousquet, E., Zhao, M., Farman, N., … Behar-Cohen, F. (2015). Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. *Progress in Retinal and Eye Research, 48*, 82–118. https://doi.org/10.1016/j.pretyeer.2015.05.003

d de Jong, E. K., Breukink, M. B., Schellevis, R. L., Bakker, B., Mohr, J. K., Fauser, S., … Boon, C. J. (2015). Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. *Ophthalmology, 122*(3), 562–570. https://doi.org/10.1016/j.jophtha.2014.09.026

Duvvari, M. R., van de Ven, J. P., Geerlings, M. J., Saksens, N. T., Bakker, B., Henkes, A., … den Hollander, A. I. (2016). Whole exome sequencing in patients with the cuticular drusen subtype of age-related macular degeneration. *PloS ONE, 11*(3), e0152047. https://doi.org/10.1371/journal.pone.0152047

Fritsche, L. G., IgI, W., Bailey, J. N., Grassmann, F., Sengupta, S., Bragg-Gresham, J. L., … Heid, I. M. (2016). A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature Genetics, 48*(2), 134–143. https://doi.org/10.1038/ng.3448

Geerlings, M. J., Kremlitzka, M., Bakker, B., Nilsson, S. C., Saksens, N. T., Lechanteur, Y. T., … den Hollander, A. I. (2017). The functional effect of rare variants in complement genes on C3b degradation in patients with age-related macular degeneration. *JAMA Ophthalmology, 135*(1), 39–46. https://doi.org/10.1001/jamaophthalmol.2016.4604

Gemenetzii, M., De Salvo, G., & Lotery, A. J. (2010). Central serous chorioretinopathy: An update on pathogenesis and treatment. *Eye, 24*(12), 1743–1756. https://doi.org/10.1038/eye.2010.130

Gilissen, C., Hoischen, A., Brunner, H. G., & Veltman, J. A. (2012). Disease gene identification strategies for exome sequencing. *European Journal of Human Genetics, 20*(5), 490–497. https://doi.org/10.1038/ejhg.2011.258

Gilissen, C., Arts, H. H., Hoischen, A., Spruijt, L., Mans, D. A., Arts, P., … Brunner, H. G. (2010). Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome. *American Journal of Human Genetics, 87*(3), 418–423. https://doi.org/10.1016/j.ajhg.2010.08.004

Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., … Genomics. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genetics in Medicine, 15*(7), 565–574. https://doi.org/10.1038/gim.2013.73

Haimovici, R., Koh, S., Gagnon, D. R., Lehrfeld, T., & Wellik, S.; Central Serous Chorioretinopathy Case-Control Study Group. (2004). Risk factors for central serous chorioretinopathy: A case-control study. *Ophthalmology, 111*(2), 244–249. https://doi.org/10.1016/j.jophtha.2003.09.024

Hoffman, J. D., Cooke Bailey, J. N., D’Aoust, L., Cade, W., Ayala-Haedo, J., Fuzzell, D., … Haines, J. L. (2014). Rare complement factor H variant associated with age-related macular degeneration in the Amish. *Investigative Ophthalmology & Visual Science, 55*(7), 4455–4460. https://doi.org/10.1167/iovs.13-13684

Jonas, J. B., & Kapppeter, B. A. (2005). Intravitreal triamcinolone acetonide and central serous chorioretinopathy. *British Journal of Ophthalmology, 89*(3), 386–387. https://doi.org/10.1136/bjo.2004.054247

Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., …Miller, D. T. (2017). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics. *Genetics in Medicine, 19*(2), 249–255. https://doi.org/10.1038/gim.2016.190

Lehmann, M., Bousquet, E., Beydoun, T., & Behar-Cohen, F. (2015). PACHYCHOROID: An inherited condition? *Retina, 35*(1), 10–16. https://doi.org/10.1097/IAE.0000000000002087

Li, H. (2014). Toward better understanding of artifacts in variant calling from high-confidence samples. *Bioinformatics, 30*(20), 2843–2851. https://doi.org/10.1093/bioinformatics/btu536

Liew, G., Quin, G., Gillies, M., & Fraser-Bell, S. (2013). Central serous chorioretinopathy: A review of epidemiology and pathophysiology. *Clinical & Experimental Ophthalmology, 41*(2), 201–214. https://doi.org/10.1111/j.1442-9071.2012.02848.x

Lin, E., Arrigg, P. G., & Kim, R. Y. (2000). Familial central serous chorioidopathy. *Graefes Archive for Clinical and Experimental Ophthalmology, 238*(11), 930–931. https://doi.org/10.1007/s004179900110

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernsntsky, A., … DePristo, M. A. (2010). The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research, 20*(9), 1297–1303. https://doi.org/10.1101/gr.107524.110

Miki, A., Kondo, N., Yanagisawa, S., Bessho, H., Honda, S., & Negi, A. (2014). Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. *Ophthalmology, 121*(5), 1067–1072. https://doi.org/10.1016/j.jophtha.2013.11.020

Moschos, M. M., Gazouli, M., Gatzionias, Z., Brouzas, D., Nomikarios, N., Sivaprasad, S., … Chatziralli, I. P. (2016). Prevalence of the complement factor H and GSTM1 genes polymorphisms in patients with central serous chorioretinopathy. *Retina, 36*(2), 402–407. https://doi.org/10.1097/IAE.0000000000000693

Nottebaum, A. F., Cagna, G., Winderlich, M., Gamp, A. C., Linnepke, R., Polaschegg, C., … Vestweber, D. (2008). VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. *Journal of Experimental Medicine, 205*(2), 2929–2945. https://doi.org/10.1084/jem.20080406

Oosterhuis, J. A. (1996). Familial central serous retinopathy. *Graefes Archive for Clinical and Experimental Ophthalmology, 234*(5), 337–341. https://doi.org/10.1007/BF00220710

Pras, E., Kristal, D., Shoshany, N., Volodarsky, D., VuliI, L., Celniker, G., … Pras, E. (2015). Rare genetic variants in Tunisian Jewish patients suffering from age-related macular degeneration. *Journal of Medical Genetics, 52*(7), 484–492. https://doi.org/10.1136/jmedgenet-2015-103130

Saksens, N. T., Geerlings, M. J., Bakker, B., Schick, T., Daha, M. R., Fauser, S., … den Hollander, A. I. (2016). Rare genetic variants associated with development of age-related macular degeneration. *JAMA Ophthalmology, 134*(3), 287–293. https://doi.org/10.1001/jamaophthalmol.2015.5592

Schellevis, R. L., van Dijk, E. H. C., Breukink, M. B., Altay, L., Bakker, B., Koeleman, B. P. C., … de Jong, E. K. (2018). Role of the complement system in chronic central serous chorioretinopathy: A
genome-wide association study. *JAMA Ophthalmology*, https://doi.org/10.1001/jamaophthalmol.2018.3190

Schubert, C., Pryds, A., Zeng, S., Xie, Y., Freund, K. B., Spaide, R. F., … Allikmets, R. (2014). Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. *Human Mutation*, 35(7), 859–867. https://doi.org/10.1002/humu.22551

Shen, J., Frye, M., Lee, B. L., Reinardy, J. L., McClung, J. M., Ding, K., … Campochiaro, P. A. (2014). Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. *J Clin Invest*, 124(10), 4564–4576. https://doi.org/10.1172/JCI74527

Sul, J. H., Cade, B. E., Cho, M. H., Qiao, D., Silverman, E. K., Redline, S., & Sunyaev, S. (2016). Increasing generality and power of rare-variant tests by utilizing extended pedigrees. *American Journal of Human Genetics*, 99(4), 846–859. https://doi.org/10.1016/j.ajhg.2016.08.015

van Dijk, E. H., Dijkman, G., Biermasz, N. R., van Haalen, F. M., Pereira, A. M., & Boon, C. J. (2016). Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome. *European Journal of Ophthalmology*, 26(5), 442–448. https://doi.org/10.5301/ejo.5000790

van Dijk, E. H. C., Schellevis, R. L., Breukink, M. B., Mohabati, D., Dijkman, G., Keunen, J. E. E., … Boon, C. J. F. (2017). Familial central serous chorioretinopathy. *Retina*. [Epub ahead of print]. https://doi.org/10.1097/IAE.000000000001966

van Dijk, E. H. C., Schellevis, R. L., van Bergen, M. G. J. M., Breukink, M. B., Altay, L., Scholz, P., … de Jong, E. K. (2017). Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. *JAMA Ophthalmology*, 135(5), 446–451. https://doi.org/10.1001/jamaophthalmol.2017.0245

Wagner, E. K., Raychaudhuri, S., Villalonga, M. B., Java, A., Triebwasser, M. P., Daly, M. J., … Seddon, J. M. (2016). Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD. *Scientific Reports*, 6, 31531. https://doi.org/10.1038/srep31531

Warrow, D. J., Hoang, Q. V., & Freund, K. B. (2013). Pachychoroid pigment epitheliopathy. *Retina*, 33(8), 1659–1672. https://doi.org/10.1097/IAE.0b013e3182953df4

Weenink, A. C., Borsje, R. A., & Oosterhuis, J. A. (2001). Familial chronic central serous chorioretinopathy. *Ophthalmologica*, 215(3), 183–187. https://doi.org/10.1159/000050855

Yang, H., & Wang, K. (2015). Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nature Protocols*, 10(10), 1556–1566. https://doi.org/10.1038/nprot.2015.105

Yannuzzi, L. A. (2010). Central serous chorioretinopathy: A personal perspective. *American Journal of Ophthalmology*, 149(3), 361–363. https://doi.org/10.1016/j.ajo.2009.11.017

Yu, Y., Triebwasser, M. F., Wong, E. K., Schramm, E. C., Thomas, B., Reynolds, R., … Seddon, J. M. (2014). Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. *Human Molecular Genetics*, 23(19), 5283–5293. https://doi.org/10.1093/hmg/ddu226

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Schellevis RL, van Dijk EHC, Breukink MB, et al. Exome sequencing in families with chronic central serous chorioretinopathy. *Mol Genet Genomic Med*. 2019;7:e576. https://doi.org/10.1002/mgg3.576